| Medicine | Presentation Title | Presentation Details |
| Pelacarsen | Pelacarsen reduces the need for lipoprotein apheresis in patients with elevated lipoprotein(a) and cardiovascular disease: The Phase 3 Lp(a)FRONTIERS APHERESIS trial | Station 12 (Research Gateway) Moderated ePoster August 29, 09:15-10:00 CEST |
| Pelacarsen | Association of elevated lipoprotein(a) with future major adverse cardiovascular events in recurrent ASCVD patients: analysis of a large US electronic health record database | Station 2 (Research Gateway) Moderated ePoster August 30, 17:15 – 18:00 CEST |
| Pelacarsen | Economic burden of elevated lipoprotein(a) in secondary prevention of atherosclerotic cardiovascular disease cohort from England | Discovery Pole (North Convention Centre) Poster August 29, 15:15 CEST |
| Leqvio | VICTORION-Difference study: Inclisiran-based strategy vs standard of care | Madrid (Main Auditorium) Hot Line August 30, 17:00 CEST |
Test Media Content with Grey Bg
Novartis is sponsoring the Eurovision Song Contest 2025 with a broader commitment to community engagement and inclusion. By supporting the ESC, we’re helping to create shared cultural and community-focused experiences that inspire progress and bring people closer together. Locally and globally.
Test Media Content null bg
paragraph.full-screen-width.paragraph--type--cardsparagraph.full-screen-width.paragraph--type--cardsparagraph.full-screen-width.paragraph--type--cards
with white bg
paragraph.full-screen-width.paragraph--type--cardsparagraph.full-screen-width.paragraph--type--cardsparagraph.full-screen-width.paragraph--type--cards